CytomX Therapeutics, Inc.Announces Appointment of Krishna Polu, M.D., as Chief Medical Officer; Promotion of Debanjan Ray, MBA, to Vice President, Business Development

Published: Jul 16, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--CytomX Therapeutics, Inc., a biotechnology company developing a new generation of targeted antibody therapeutics, today announced that it has appointed Krishna Polu, M.D., to the newly created position of chief medical officer. In this role, Dr. Polu oversees preclinical and clinical development of the Company’s diversified pipeline of empowered antibodies, including Probodies™, Probody-Drug Conjugates (PDCs), multispecific Probodies, and other novel Probody formats.

Help employers find you! Check out all the jobs and post your resume.

Back to news